Scisparc signs non-binding letter of intent for spin off of advanced clinical stage pharmaceutical portfolio to publicly traded company

According to the agreement, scisparc's pharmaceuticals assets are valued at approximately $11.6 million tel aviv, israel, july 08, 2024 (globe newswire) -- scisparc ltd. (nasdaq: sprc) (“company” or “scisparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today it signed a non-binding letter of intent (the “loi”) to spin off its advanced clinical stage pharmaceutical portfolio and its equity stake in scisparc nutraceuticals inc. (collectively, the “target assets”).
SPRC Ratings Summary
SPRC Quant Ranking